Systems-level liquid biopsy in advanced prostate cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Castration-resistant prostate cancer (CRPC) treatment relies on androgen receptor signaling inhibitors (ARSIs).
• Resistance to ARSIs is a significant clinical challenge, driven by AR locus aberrations or lineage plasticity.
• Current monitoring methods for ARSI resistance in CRPC are limited.

Purpose of the Study:

• To review advancements in understanding CRPC treatment resistance mechanisms using liquid biopsy.
• To explore novel liquid biopsy-based disease characterization methods.
• To emphasize the clinical potential of multi-omics profiling for detecting therapeutic resistance.

Main Methods:

• Review of research-grade liquid biopsy assays in CRPC.
• Analysis of genomic and transcriptomic features detected via liquid biopsy.
• Exploration of multi-omics molecular profiling approaches.

Main Results:

• Liquid biopsy assays reflect tumor tissue features and detect various resistance signatures in CRPC.
• Novel disease characterization methods using liquid biopsy have been developed.
• Multi-omics profiling using liquid biopsy shows potential for comprehensive resistance detection.

Conclusions:

• Liquid biopsy is a minimally invasive tool for longitudinal monitoring of CRPC progression and resistance.
• Advanced liquid biopsy assays provide deeper insights into resistance mechanisms than current clinical tests.
• Routine multi-omics liquid biopsy assessment can enhance prognostication and treatment strategies for CRPC patients.